Gliomas are the most common
neoplasms in the central nervous system. The lack of efficacy of
glioma therapies necessitates in-depth studies of
glioma pathology, especially of the underlying molecular mechanisms that transform normal glial cells into
tumor cells. Here we report that a
deubiquitinating enzyme,
ubiquitin-specific protease 2a (USP2a), and its substrate,
fatty acid synthase (FASN), are over-expressed in
glioma tissue. Using real-time quantitative polymerase chain reaction (PCR), Western blot and immunohistochemistry, we examined the expression and cellular distribution of USP2a and FASN in human
glioma tissues. The expression patterns of USP2a and FASN correlated with the pathologic and clinical characteristics of the patients. Real-time PCR analysis showed that the expression levels of USP2a and its substrate FASN were higher in high-grade (World Health Organization [WHO] grades III and IV)
glioma tissues than in low-grade (WHO grades I and II)
glioma tissues. Western blot analysis indicated that the average optical densitometry ratio of USP2a and its substrate FASN in high-grade
gliomas was higher than in low-grade
gliomas. Moreover, statistical analysis of grade-classified
glioma samples showed that the level of USP2a and FASN expression increased with the elevation of the WHO grade of
glioma. USP2a
protein expression was detected in the nucleus of
glioma tissues and an increase in expression was significantly associated with the elevation of the WHO grade of
glioma by immunohistochemistry. These findings expand our understanding of the molecular profiling of
glioma and could shed light on new diagnostic criteria for
gliomas.